share_log

HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $25 Price Target

HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $25 Price Target

HC Wainwright & Co.重申買入BriaCell Therapeutics,維持25美元的目標股價
Benzinga ·  2023/06/28 06:12

HC Wainwright & Co. analyst Emily Bodnar reiterates BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and maintains $25 price target.

HC Wainwright & Co. 分析師艾米麗·博德納爾重申了BriaCell Therapeutics(納斯達克股票代碼:BCTX)的買入,並維持25美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論